

TEST REPORT

Test requested: *In vitro* cytotoxicity test-MTT.

Test material:

Number of test materials: 1

Nature of test material: Herbo mineral formulation

Test material Name: Onconil

Study dates:

Test material received: 21 Jan, 2023
Begin of testing: 07 Feb, 2023
End of testing 25 Mar, 2023
Final report: 10 Apr, 2023

• Purpose

The purpose of this test is to determine the potential cytotoxicity of the test material on a mammalian cell culture.

• Equipment and reagents

A) Cell lines:

Sr.No	Name of cell line	Tissue origin Type of cell line
1	Vero	African green monkey kidney Normal
2	MCF-7	Breast; Mammary gland of Adenocarcinoma
		human

B) Reagents

- 1. Minimum Essential Medium-MEM (Gibco)
- 2. Fetal Bovine Serum-FBS (HiMedia)
- 3. Trypsin Versene Phosphate Glucose-TPVG (HiMedia)
- 4. Phosphate Buffered Saline-PBS (HiMedia)
- 5. Antibiotic-Antimycotic solution (HiMedia)
- 6. MTT powder (HiMedia)
- 7. Dimethyl Sulfoxide-DMSO (HiMedia)
- 8. Doxorubicin Hydrochloride injection IP (Fresenius Kabi)
- 9. Liquid Nitrogen (LN₂)

C) Consumables

- 1. Tissue Culture Flask (T-25) (HiMedia)
- 2. 96 Well plates (Tarsons)
- 3. Disposable Serological Pipettes (2,5,10,25 mL) (HiMedia)
- 4. Cryovials (1.8 mL)
- 5. Centrifuge tubes (15,50 mL)



- 6. Syringe and Syringe driven filters (0.22,0.45 μm)
- D) Equipments:
- 1. Biosafety Cabinet (Microfilt)
- 2. CO₂ Incubator (Remi)
- 3. Centrifuge (Remi)
- 4. Inverted Microscope (Olympus)
- 5. ELISA Reader (Thermo Scientific)
- 6. Water bath (Equitron)
- 7. 2-8°C Refrigerator (Samsung)

• Experiment design

Test method

Aseptic procedures were used for handling cell cultures. Vero and MCF-7 cells were cultured in MEM (10% FBS, 1% Penicillin-Streptomycin solution) at 37°C in a 5% CO₂, then digested by 0.25% TPVG to get single cell suspension. Approximately 1.5 x 10⁶ cells/ml suspension were obtained by centrifuging (1400 rpm, 5 min) and re-suspending in 1 ml MEM.

The resuspended cells were counted using Neubaeur's chamber and 100 μ l of 2 x 10⁴ cells per well in 96-well plate was seeded, and cultured in incubator (5% CO₂,37°C, >90% humidity). Cell morphology was evaluated to verify that the monolayer was satisfactory.

After 24 hours, the spent culture medium was decanted. A stock solution of 10 mg/ml of test material was prepared in DMSO. The 96-well plates were then treated with $100 \, \mu l$ of extract of test material at different concentrations, Positive control- Doxorubicin, and Cell control respectively. The 96-well plate was incubated at 37°C and 5% CO₂ in incubator for 24 hours. The test assay was performed in triplicates. The time dependent assay was also performed at 24, 48 & 72 hrs. with repeated doses.

After incubation, the cell morphology was observed and 20 μ l MTT (5mg/ml) was added to each well and then incubated at 37°C and 5% CO₂ for 4 hours. The medium in each well was decanted and 100 μ l DMSO was added to each well to terminate the assay. The experimental plate was evaluated using spectrophotometer with the measurement wavelength at 570 nm.

• Calculations and Statistical Analysis

The concentration at which the OD of treated cells was reduced by approximately 50% with respect to the untreated control was determined to be IC50. The percentage viability of cells in the treatment groups was calculated with the help of the following formula,

% Cell viability = [average OD of treated cells/average OD of control cells] \times 100 Selectivity Index: IC50 of Normal cell line / IC50 of cancer cell line

• Evaluation criteria

- 1. The lower the % Viability value, the higher the cytotoxic potential of the test article is.
- 2. The higher the Selectivity Index value i.e., >1 theoretically more effective and safer a test substance would be during in-vivo treatment.



• Results of the test

1. Results of the cell morphology




Figure 1: Morphological observation of cells under inverted microscope (10X)

2. Results of the Cytotoxicity assay

Assay 1:

	MCF-7	: Onconil			Vero: (Onconil	
Conc	Average	%	% Cell	Conc	Average	%	% Cell
μg/ml	OD	Viability	death	μg/ml	OD	Viability	death
5000	0.16	46.78	53.22	5000	0.145	15.66	84.34
1000	0.18	51.20	48.80	1000	0.168	18.14	81.86
500	0.19	54.66	45.34	500	0.257	27.73	72.27
100	0.25	72.72	27.28	100	0.461	49.68	50.32
50	0.28	79.83	20.17	50	0.578	62.32	37.68
10	0.44	125.74	-25.74	10	0.838	90.30	9.70
5	0.39	113.26	-13.26	5	0.895	96.48	3.52
IC50 4330 μg/ml			IC50		167.9 μg/ml	•	



Assay 2:

	MCF-	7: Onconil			Vero	: Onconil	
Conc	Average	%	% Cell	Conc	Average	%	% Cell
μg/ml	OD	Viability	death	μg/ml	OD	Viability	death
5000	0.191	33.22	66.78	500	0.300	37.32	62.68
4000	0.282	49.07	50.93	400	0.307	38.19	61.81
3000	0.325	56.56	43.44	300	0.318	39.60	60.40
2000	0.345	60.05	39.95	200	0.349	43.50	56.50
1000	0.262	45.64	54.36	100	0.415	51.68	48.32
500	0.434	75.61	24.39	50	0.543	67.58	32.42
IC50 3766.25 μg/ml				IC50		195.26 μg/ml	

Assay 3:

	MCF-7:	Onconil		Vero : Onconil			
Conc	Average	%Viability	% Cell	Conc	Average	%Viability	% Cell
μg/ml	OD	% Viability	death	μg/ml	OD	% Viability	death
900	0.152	36.80	63.19	900	0.141	24.90	75.10
600	0.130	31.55	68.44	600	0.166	29.32	70.68
400	0.102	24.61	75.38	400	0.202	35.81	64.19
300	0.118	28.49	71.50	300	0.229	40.53	59.47
200	0.091	21.95	78.04	200	0.250	44.31	55.69
150	0.114	27.52	72.47	150	0.261	46.14	53.86
IC50	IC50 1715.88 μg/ml			IC50	1	14.89 μg/ml	

Assay 4: Time Dependent Assay

MCF-7: Onconil - 24 Hours						Vero: Onco	nil - 24 Hour	s
Conc µg/ml	Average OD	% Viability	% Cell death		Conc µg/ml	Average OD	% Viability	% Cell death
3000	0.195	43.31	56.69		3000	0.119	26.39	73.61
2000	0.172	38.06	61.94		2000	0.136	30.08	69.92
1000	0.123	27.20	72.80		1000	0.170	37.62	62.38
500	0.077	17.00	83.00		500	0.195	43.16	56.84
300	0.092	20.40	79.60		300	0.210	46.49	53.51
150 0.071 15.67 84.33		150	0.266	58.91	41.09			
IC50		3462 με	3462 μg/ml		I	C50	156.67	μg/ml



MCF-7: Onconil - 48 Hours					Ve	ero : Onco	nil -48 Hours	S
Conc	Average	%	% Cell		Conc	Average	%	% Cell
μg/ml	OD	Viability	death		μg/ml	OD	Viability	death
3000	0.139	24.60	75.40		3000	0.110	19.41	80.59
2000	0.127	22.42	77.58		2000	0.108	19.12	80.88
1000	0.120	21.30	78.70		1000	0.106	18.70	81.30
500	0.118	20.83	79.17		500	0.098	17.40	82.60
300	0.117	20.65	79.35		300	0.095	16.81	83.19
150	0.113	19.94	80.06		150	0.088	15.58	84.42

MCF-7: Onconil - 72 Hours						Vero: Or	nconil -72 Ho	ours
Conc	Average	%	% Cell		Conc	Average	%	% Cell
μg/ml	OD	Viability	death		μg/ml	OD	Viability	death
3000	0.249	33.88	66.12		3000	0.309	42.10	57.90
2000	0.234	31.93	68.07		2000	0.256	34.88	65.12
1000	0.186	25.34	74.66		1000	0.240	32.70	67.30
500	0.130	17.76	82.24		500	0.160	21.80	78.20
300	0.128	17.48	82.52		300	0.117	15.94	84.06
150	0.086	11.67	88.33		150	0.094	12.76	87.24
IC50		5081.43	μg/ml		IC	C50	3828.89	μg/ml

Results of Positive Control

Vero	: Positive Co	ontrol-Doxor	ubicin	MCF-	7: Positive Co	ontrol-Doxo	rubicin
Conc	Average	%	% Cell	Conc	Average	%	% Cell
μg/ml	OD	Viability	death	μg/ml	OD	Viability	death
20	0.496	53.41	46.59	20	0.291	50.75	49.2
15	0.565	60.88	39.12	15	0.321	55.87	44.1
10	0.531	57.26	42.74	10	0.400	69.63	30.3
5	0.555	59.81	40.19	5	0.420	73.17	26.8
2	0.502	54.13	45.87	2	0.425	73.98	26.0
IC50		22.1 μg/ml	•	IC50	2	20.83 μg/ml	·

Cumulative results of 3 assays:

Assay	MCF-7(IC50) µg/ml	Vero (IC50) μg/ml	Selectivity Index
1	4330	167.9	0.04
2	3766.25	195.26	0.05
3	1715.88	114.89	0.07
Average	3270.71	159.35	0.11

% Cell death

> 49.25 44.13

30.37

26.83

26.02



Conclusion

- 1. Average IC50 value of Test material on MCF-7 cell line is **3270.71** μg/ml.
- 2. Average IC50 value of Test material on Vero cell line is $159.35 \,\mu g/ml$.
- 3. IC50 value of Positive control correlates with the literature.
- 4. The Selectivity Index (SI) of Test material is **0.11** hence it is toxic to normal cells.
- 5. The test material shows antiproliferative activity on human breast adenocarcinoma cell line-MCF7 and may be evaluated for other cancer cell lines.

• Authorization:

Particulars	Name	Designation	Signature
Performed by	Manasi V Chavan	Research Assistant	
	Prachi V Prasad	Research Assistant	
Supervised by	Dr. Vaibhav S Ladke	Research Associate	
Quality Assurance	Avinash A Lendave	Quality Manager	
Approved by	Dr. Chandrashekhar Raut	Laboratory Director	

References:

- 1. ISO 10993-5:2009, Biological evaluation of medical devices: Part 5: Tests for in vitro cytotoxicity.
- 2. Indrayanto G, Putra GS, Suhud F. 2021. Validation of in-vitro bioassay methods: Application in herbal drug research. Profiles Drug Subst Excip Relat Methodol.; 46:273-307. doi: 10.1016/bs.podrm.2020.07.005.
- 3. General Guidelines for Drug Development of Ayurvedic Formulations 2018. Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India, New Delhi. www.ccras.nic.in